These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 11362105)

  • 21. South Africans win MTCT court case.
    Achmat Z
    WORLD; 2002 Jan; (129):6. PubMed ID: 12141243
    [No Abstract]   [Full Text] [Related]  

  • 22. Follow-up survey of women who have undergone a prevention of mother-to-child transmission program in a resource-poor setting in South Africa.
    Peltzer K; Mosala T; Dana P; Fomundam H
    J Assoc Nurses AIDS Care; 2008; 19(6):450-60. PubMed ID: 19007723
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Time to move on. More questions about single-dose nevirapine.
    Clayden P
    GMHC Treat Issues; 2004; 18(11-12):9-10. PubMed ID: 15751137
    [No Abstract]   [Full Text] [Related]  

  • 24. Which ART regimen is best after receipt of single-dose nevirapine?
    Ryan CT
    AIDS Clin Care; 2009 Jan; 21(1):6. PubMed ID: 19230057
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy in Thai HIV-infected children aged two years or less.
    Puthanakit T; Aurpibul L; Sirisanthana T; Sirisanthana V
    Pediatr Infect Dis J; 2009 Mar; 28(3):246-8. PubMed ID: 19165130
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Understanding the reverse transcriptase inhibitors in HIV.
    Edmonds-Ogbuokiri J
    Fac Notes (New Orleans La); 1998; 10(6):13-5. PubMed ID: 11366142
    [TBL] [Abstract][Full Text] [Related]  

  • 27. FDA advisory on nevirapine.
    AIDS Treat News; 2005 Jan; (409):7. PubMed ID: 15791716
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Single-dose jeopardizes long-term therapy.
    Clayden P
    GMHC Treat Issues; 2004; 18(11-12):6-8. PubMed ID: 15751136
    [No Abstract]   [Full Text] [Related]  

  • 29. Association of cord blood nevirapine concentration with reported timing of dose and HIV-1 transmission.
    Jackson JB; Parsons T; Musoke P; Nakabiito C; Donnell D; Fleming T; Mirochnick M; Mofenson L; Fowler MG; Mmiro F; Guay L
    AIDS; 2006 Jan; 20(2):217-22. PubMed ID: 16511414
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized trial comparing initial HAART regimens of nelfinavir/nevirapine and ritonavir/saquinavir in combination with two nucleoside reverse transcriptase inhibitors.
    Kirk O; Lundgren JD; Pedersen C; Mathiesen LR; Nielsen H; Katzenstein TL; Obel N; Gerstoft J
    Antivir Ther; 2003 Dec; 8(6):595-602. PubMed ID: 14760893
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Let nevirapine do what it does best.
    Huff B
    GMHC Treat Issues; 2002 Mar; 16(3):10-1. PubMed ID: 12004796
    [No Abstract]   [Full Text] [Related]  

  • 32. Nevirapine is now available for use in HIV-infected children.
    Fac Notes (New Orleans La); 1999; 11(2):11. PubMed ID: 11810878
    [No Abstract]   [Full Text] [Related]  

  • 33. Unrecognized near-fatal hyperlactatemia in an HIV-infected infant exposed to nucleoside reverse transcriptase inhibitors.
    Koh MT
    Int J Infect Dis; 2007 Jan; 11(1):85-6. PubMed ID: 16581278
    [No Abstract]   [Full Text] [Related]  

  • 34. Delaying maternal NVP-based ART more effective.
    Alcorn K
    IAPAC Mon; 2007 Jan; 13(1):11-2. PubMed ID: 17523244
    [No Abstract]   [Full Text] [Related]  

  • 35. Single dose theory.
    Huff B
    GMHC Treat Issues; 2004; 18(11-12):1-5. PubMed ID: 15751135
    [No Abstract]   [Full Text] [Related]  

  • 36. Women exposed to single-dose nevirapine in successive pregnancies: effectiveness and nonnucleoside reverse transcriptase inhibitor resistance.
    Martinson NA; Morris L; Johnson J; Gray GE; Pillay V; Ledwaba J; Dhlamini P; Cohen S; Puren A; Steyn J; Heneine W; McIntyre JA
    AIDS; 2009 Apr; 23(7):809-16. PubMed ID: 19287298
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Single-dose Nevirapine during pregnancy.
    Sax PE
    AIDS Clin Care; 1999 Oct; 11(10):84-5. PubMed ID: 11366708
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nevirapine concentration in cervicovaginal and oropharyngeal secretions after single-dose administration to the mother.
    Harms G; Kunz A; Karcher H; Mugenyi K; Kurowski M
    Antivir Ther; 2005; 10(6):777. PubMed ID: 16218178
    [No Abstract]   [Full Text] [Related]  

  • 39. Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children.
    Sáez-Llorens X; Violari A; Deetz CO; Rode RA; Gomez P; Handelsman E; Pelton S; Ramilo O; Cahn P; Chadwick E; Allen U; Arpadi S; Castrejón MM; Heuser RS; Kempf DJ; Bertz RJ; Hsu AF; Bernstein B; Renz CL; Sun E
    Pediatr Infect Dis J; 2003 Mar; 22(3):216-24. PubMed ID: 12634581
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Widespread vitiligo after erythroderma caused by nevirapine in a patient with AIDS.
    Ramírez-Hernández M; Sánchez-Sierra B; Martínez-Escribano JA
    Acta Derm Venereol; 2007; 87(5):442-3. PubMed ID: 17721659
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.